Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 6, 2008, Pages 679-683

  Krishna, R ^a   Bergman, A J ^a   Jin, B ^a   Fallon, M ^a   Cote, J ^a   Van Hoydonck, P ^a   Laethem, T ^a   Gendrano III, I N ^a   Van Dyck, K ^a   Hilliard, D ^a   Laterza, O ^a   Snyder, K ^a   Chavez Eng, C ^a   Lutz, R ^a   Chen, J ^a   Bloomfield, D M ^a   De Smet, M ^a   Van Bortel, L M ^b   Gutierrez, M ^c   Al Huniti, N ^d   Dykstra, K ^d   Gottesdiener, K M ^a   Wagner, J A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Comprehensive Phase One Inc ^*  (United States)

^d PHARSIGHT CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN B; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; MK 0859; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DYSLIPIDEMIA; FAT INTAKE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID DIET; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; TASTE DISORDER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHOLESTEROL ESTER TRANSFER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 56549117314     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.109     Document Type: Article

References (26)

1. Tall, A.R. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34, 1255-1274 (1993).
2. Guyard-Dangremont, V., Desrumaux, C., Gambert, P., Lallemant, C. & Lagrost, L. Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 120, 517-525 (1998).
3. Clark, R.W. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24, 490-497 (2004).
4. de Grooth, G.J. et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105, 2159-2165 (2002).
5. Tanne, J.H. Pfizer stops clinical trials of heart drug. BMJ 333, 1237 (2006).
6. Barter, P.J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Eng. J. Med. 357, 2109-2122 (2007).
7. Thuren, T., Longcore, A. & Powell, C. Torcetrapib combined with atorvastatin raises HDL-C, lowers LDL-C, and is well tolerated. Results from a Phase 2, dose-ranging clinical trial [abstract]. American Heart Association Annual Meeting, Dallas, TX, 2005.
8. Davidson, M.H., McKenney, J.M., Shear, C.L. & Revkin, J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 48, 1774-1781 (2006).
9. McKenney, J.M., Davidson, M.H., Shear, C.L. & Revkin, J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. 48, 1782-1790 (2006).
10. Kastelein, J.P. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620-1630 (2007).
11. Nissen, S.E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316 (2007).
12. O'Neill, E.A. et al. Identification and characterization of anacetrapib (MK-0859): a novel CETP inhibitor [abstract]. XVI Int. Symp. Drugs Affecting Lipid Metabolism, New York, NY, 2007.
13. Forrest, M.J. et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by an increase in circulating aldosterone levels [abstract]. American Heart Association Meeting, 2007.
14. Gibaldi, M. & Perrier, D. Pharmacokinetics (Marcel Dekker, New York, 1982).
15. Eveland, S.S. et al. A high precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3,456-well assay technology. Anal. Biochem. 368, 239-249 (2007).
16. Nauck, M., Warnick, G.R. & Rifai, N. Methods for the measurement of LDL-cholesterol: a critical assessment of direct measurement by homogenous assays versus calculation. Clin. Chem. 48, 236-254 (2002).
17. Bergman, A. et al. Optimizing dose selection using population PK/PD modeling and simulation for the CETP inhibitor anacetrapib (MK-0859) in healthy subjects [abstract]. American Association of Pharmaceutical Scientists Annual Meeting, Anaheim, CA, 2007.
18. Krishna, R. et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370, 1907-1914 (2007).
19. Bloomfield, D.M. et al. Efficacy and safety of the CETP inhibitor MK-0859 in dyslipidemic patients [abstract]. XVI Int. Symp. Drugs Affecting Lipid Metabolism (DALM), New York, NY, 2007.
20. Clark, RW, Ruggeri, R.B., Cunningham, D. & Bamberger, M.J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47, 537-552 (2006).
21. Mandema, J.W. et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 7, E513-E522 (2005).
22. Thuren, T., Longcore, A., Powell, C., Strand, J., Durham, K. & Shear, C. Effects of torcetrapib and/or atorvastatin on HDL and LDL particle type, composition, and size: results from a phase 2 trial. American Heart Association Annual Meeting, Dallas, TX, 2005.
23. Nicholls, S.J. et al. Changes in levels of high density lipoprotein cholesterol predict the impact of torcetrapib on progression of coronary atherosclerosis: insights from ILLUSTRATE [abstract]. American Heart Association Annual Meeting, Orlando, FL, 2007.
24. Yvan-Charvet, L. et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 27, 1132-1138 (2007).
25. Krishna, R., Bergman et al. Pharmacokinetics and pharmacodynamics of single doses of MK-0859, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects [abstract]. XVI Int. Symp. Drugs Affecting Lipid Metabolism, New York, NY, 2007.
26. Perlman, M.E. et al. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib. Int. J. Pharm. 351, 15-22 (2007).